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within a habitat (5–7). Population density–
dependent olfactory plasticity may serve as one
of such adaptive mechanisms. Our results indicate
that nep-2 regulates olfactory plasticity by acting
in a cell-nonautonomous manner. Mammals pos-
sess seven neprilysin family proteins: neprilysin,
endothelin-converting enzyme 1 (ECE1), ECE2,
phosphate-regulatingneutral endopeptidase (PHEX),
neprilysin-2, damage-induced neuronal endopep-
tidase (DINE), and Kell (16). Although little is
known about the loss-of-function phenotypes of
the neprilysin family proteins, recent biochemical
studies revealed that neprilysin scavenges amy-
loid b peptide efficiently and with this mechanism
can prevent Alzheimer’s disease (17). On the basis
of our observations, we propose a model in which
SNET-1 peptide is secreted as an environmental
signal that prevents olfactory plasticity and NEP-2
turns off the SNET-1 signals by degrading the
excess peptides, creating a balance sensitive to
environmental signals. By acting on an unknown
receptor in the olfactory sensory circuit, SNET-1
negatively regulates olfactory plasticity (Fig. 4G
and fig. S14). Given that daf-22, nep-2, and snet-1
regulate the plasticity of the response to several
types of odorants (fig. S3), the pheromonal infor-
mationmay also regulate other behaviors through
the peptide signaling. Our identification of the
SNET-1 pathway that regulates olfactory plastic-
ity sheds light on the complexity of the regulatory
network underlying simple sensory behavior in
C. elegans and suggests similar regulation might
be present in other animals.
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A Unifying Genetic Model
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Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy in adults
that is foremost characterized by progressive wasting of muscles in the upper body. FSHD is
associated with contraction of D4Z4 macrosatellite repeats on chromosome 4q35, but this
contraction is pathogenic only in certain “permissive” chromosomal backgrounds. Here, we show
that FSHD patients carry specific single-nucleotide polymorphisms in the chromosomal region
distal to the last D4Z4 repeat. This FSHD-predisposing configuration creates a canonical
polyadenylation signal for transcripts derived from DUX4, a double homeobox gene of unknown
function that straddles the last repeat unit and the adjacent sequence. Transfection studies
revealed that DUX4 transcripts are efficiently polyadenylated and are more stable when expressed
from permissive chromosomes. These findings suggest that FSHD arises through a toxic gain of
function attributable to the stabilized distal DUX4 transcript.
Autosomal dominant FSHD (FSHD1;OMIM158900) is a common form of musculardystrophy, affecting 1 in 20,000 people,
that is characterized by progressive and often
asymmetric weakness and wasting of facial,
shoulder girdle, and upper arm muscles (1). The
disorder is most often caused by contraction of the
D4Z4 macrosatellite repeat array in the subtelo-
meric region of chromosome 4q35 (2). This poly-
morphic macrosatellite repeat normally consists
of 11 to 100 D4Z4 units, each 3.3 kb in size and
ordered head-to-tail. Patientswith FSHD1have one
repeat array of 1 to 10 units (Fig. 1A). At least one
unit of D4Z4 is required to develop FSHD (3).
D4Z4 contraction needs to occur on a specific
chromosomal background to cause FSHD. The
chromosome 10q subtelomere contains an almost
identical repeat array, but contractions on this
chromosome are nonpathogenic (Fig. 1A). Trans-
located copies of the chromosome 4 and chromo-
some 10 repeat units are frequently encountered
on either chromosome end (4). This complex
genetic situation, inwhich genetically almost iden-
tical repeat units can be exchanged between both
chromosomes with apparently discordant patho-
logical consequences, has long hampered the iden-
tification of the disease mechanism.
Disease models were postulated in which
D4Z4 repeat contractions cause chromatin re-
modeling and transcriptional deregulation of genes
close to D4Z4. Indeed, contracted D4Z4 repeat
arrays show partial loss of DNAmethylation and
of heterochromatic histone 3 lysine 9 trimethyla-
tion and heterochromatin protein 1gmarkers con-
sistent with a more open chromatin structure (5, 6).
Transcriptional up-regulation of genes proximal to
D4Z4 was reported in FSHD1 patients (7) but
could not be confirmed (8, 9).
Exchanges between repeat units of chromo-
somes 4 and 10 occur much less frequently than
anticipated: Most translocated repeat units are
relicts of ancient translocation events between
chromosomes 4q and 10q (10). Of the two distal
chromosome 4q configurations, 4qA and 4qB,
only contractions of the 4qA form led to FSHD1
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(11). Genetic follow-up studies unveiled consist-
ent polymorphisms in the FSHD locus, resulting
in the recognition of at least 17 genetic variants of
distal 4q (10). Contractions in the common var-
iant 4A161 cause FSHD1, whereas contractions
in many other variants, such as the common
4B163, do not cause FSHD1 (Fig. 1A) (12). Thus,
it appears that chromosome 4A161–specific
sequence variants are causally related to FSHD.
Because at least one D4Z4 unit is necessary to
cause disease, we reasoned that the minimal
pathogenic region might reside in the first or the
last unit. The distal unit of the D4Z4 repeat was
recently shown to have a transcriptional profile
that differs from internal units (13, 14). Although
the major transcript in each unit is the DUX4
gene, which codes for a double homeobox pro-
tein, none of these transcripts seem to be stable,
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Fig. 1. Schematic overview showing the minimal genetic requirement for
FSHD1. (A) The D4Z4 repeat array on chromosome 4q35 (open triangles) and
its homolog on chromosome 10q26 (closed triangles), indicating the location
of the simple sequence length polymorphism (SSLP) and 4qA/4qB polymorphisms
that define the genetic background of the repeat. Patients with FSHD1 have a
D4Z4 repeat array size of 1 to 10 units on 4qA but not on 4qB or 10q chromo-
somes. (B) Schematic of the D4Z4 repeat and flanking sequences on A, A-L (with an
extended distal D4Z4 repeat unit), and B chromosomes. Each D4Z4 unit is defined
by the KpnI restriction site (K). The proximal and distal regions that were sequenced
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Fig. 2. DUX4 expression analysis after transfection of the distal D4Z4
unit and flanking pLAM sequence into C2C12 mouse myoblast cells. (A)
Northern blot analysis of C2C12 mouse myoblast cells transfected with
genomic D4Z4 constructs [see (B)] derived from permissive (lanes 1 to
4) or nonpermissive (lanes 6, 7, and 9) chromosomes or constructs in
which the poly(A) signals from nonpermissive chromosomes are re-
placed by those from permissive chromosomes (4PAS, lanes 8 and 10)
and vice versa (10mPAS, lane 5). Only constructs with canonical poly(A)
signals show a DUX4 transcript. Cotransfected EGFP gene was used as a
control. (B) Schematic of the transfected sequence, including the distal
D4Z4 unit and flanking pLAM sequence. The DUX4 gene and the poly(A) signal are part of
the transfected sequence. The main spliced DUX4 transcript and its open reading frame
(ORF) are indicated. The primers used to quantify polyadenylation efficiency are indicated.
The boxed area shows the design of the assay to infer the polyadenylation efficiency of the
DUX4 poly(A) signal. The forward primer straddles exons 2 and 3 and is therefore specific
for the spliced DUX4 transcript. The primer set proximal to the poly(A) signal (PAS) and a
primer set using the same forward primer but a reverse primer distal to the poly(A) signal
(DAS) are indicated, as well as the expected PAS/DAS ratios. (C) Bar diagram with the observed
PAS/DAS ratios of permissive chromosomes (lanes 3 and 4), nonpermissive chromosomes (lanes
6, 7, and 9), and permissive chromosomes in which the poly(A) signal is replaced for a se-
quence derived from a nonpermissive chromosome (10mPAS, lane 5) or vice versa (4PAS, lanes 8 and 10), or of pathogenic chromosomes derived from
families F1 and F3 (lanes 1 and 2). Lane 11 is a negative control. ND, not detected. Error bars represent values of quadruple experiments with standard
errors of the mean.

































probably due to the absence of a polyadenylation
signal in internal D4Z4 units. Spliced and un-
spliced transcripts of the DUX4 gene in the last
unit, however, use a unique 3′ untranslated region
(UTR) in the pLAM region (15), which is im-
mediately distal to this last unit (Figs. 1B and 2B)
and which contains a poly(A) signal that presum-
ably stabilizes this distal transcript (13, 14). The
DUX4 transcript of the distal D4Z4 unit encom-
passes two facultative introns in the 3′UTR.When
expressed in C2C12 muscle cells, DUX4 causes
a phenotype compatible with molecular observa-
tions in FSHD (16). This distal DUX4 transcript
can be observed in FSHD1 myotubes but not in
control myotubes (fig. S1) (17).
To investigate why the 4A161 chromosome
is permissive for disease, we compared the se-
quence of the 4A161 chromosome with that of
common, nonpermissive 4B163 and 10A166 chro-
mosomes. We could not identify a sequence sig-
nature in the proximal D4Z4 unit of the repeat
array that explained the permissiveness of the
4A161 chromosome (fig. S2). However, imme-
diately distal to D4Z4, in the adjacent pLAM se-
quence, we found a polymorphism potentially
affecting polyadenylation of the distal DUX4 tran-
script. TheDUX4 poly(A) signal ATTAAA, which
is commonly used in humans (18), is present on the
permissive 4A161 chromosome, whereas the cor-
responding ATCAAA sequence on chromosome
10q is not known to be a poly(A) signal (fig. S2).
Nonpermissive 4qB chromosomes, like 4B163,
lack pLAM altogether, including this poly(A) site
(Fig. 1B). Another nonpermissive 10qA chromo-
some (10A176T) (10) carries ATTTAA at this
position, which is also not known as a poly(A)
signal (figs. S2 and S3). In silico poly(A) signal
prediction programs (19, 20) also recognized the
DUX4 poly(A) signal in 4A161 but failed to
identify potential poly(A) signals in nonpermissive
chromosomes 10A166 and 10A176T.
To explore whether these polymorphisms af-
fect the distalDUX4 transcript, we transfected the
last D4Z4 unit and flanking pLAM sequence of
permissive and nonpermissive chromosomes in
C2C12 cells and assessed the stability of the
distal DUX4 transcript by Northern blot analysis
(Fig. 2A). We also examined the relative potency
of the poly(A) signals on the permissive and non-
permissive chromosomes in directing polyade-
nylation of the distalDUX4 transcript. We studied
polyadenylation site usage indirectly by using a
quantitative reverse transcription polymerase chain
reaction (21) in which we compared DUX4 tran-
script levels proximal and distal of the poly(A)
site (Fig. 2B). The use of the predicted poly(A)
signal was verified by 3′ rapid amplification of
cDNA ends (fig. S4). We also transfected con-
structs in which the poly(A) signal of permissive
chromosomes was replaced by those of nonper-
missive chromosomes, and vice versa. We found
that DUX4 transcripts were stable (Fig. 2A) and
efficiently polyadenylated (Fig. 2C) when we
used constructs from permissive chromosomes or
when the poly(A) signal of a permissive chromo-
some was introduced on constructs derived from
nonpermissive chromosomes. Consistently, when
constructs derived from nonpermissive chromo-
somes were transfected, no DUX4 transcripts
could be detected on Northern blot and polyad-
enylation was inefficient. DUX4 stability and
polyadenylation efficiency decreased when the
poly(A) signal of permissive constructs was re-
placed by nonpermissive sequences. Altogether,
constructswith a bona fide poly(A) signal produced
stable transcripts and showed polyadenylation
efficiency that was 4 to 16 times as high as con-
structs with amutation in the poly(A) signal. This
suggests that increased polyadenylation, and hence
stability, of the distalDUX4 transcript may be cen-
trally involved in FSHD pathogenesis.
We next studied FSHD1 patients with un-
usual hybrid D4Z4 repeat array structures that
contain mixtures of 4-type and 10-type units. We
identified four families (F1 to F4) with one or
more individualswithFSHD1, carrying a contracted
D4Z4 repeat array that commences with 10-type
units and ends with 4-type units (Fig. 3). In
family F3, we identified a patient with a de novo
meiotic rearrangement between chromosomes 4q
and 10q, leaving one and a half 10-type repeat
units on a permissive 4A161 chromosome. In
family F4, the mildly affected father is a mosaic
FSHD1 patient (22) due to a mitotic contraction
of such hybrid repeat array. The mosaic patho-
genic repeat starts with two and a half 10-type
D4Z4 units and ends with one and a half 4-type
repeat units. This repeat array in the father was
transmitted to his affected son, demonstrating its
pathogenicity, and, unexpectedly, it was found to
reside on chromosome 10 (fig. S6). Only the dis-
tal end of the D4Z4 repeat array was transferred
to chromosome 10q, so that none of the FSHD
candidate genes located proximal to the D4Z4
repeat array were cotransferred to chromosome
10 (fig. S6). This report of a FSHD1 family linked
to chromosome 10 apparently precludes a key
role for proximal 4q genes in the pathogenesis of
FSHD. Altogether, all unusual FSHD1-causing
repeat arrays reported here thus share the com-
monality of a terminal 4qA repeat unit with a
directly adjacent pLAM sequence.
We also analyzed other disease-permissive
chromosome 4 variants (fig. S7): 4A161L was
previously described (10, 15), whereas 4A159
and 4A168 are newly discovered uncommon
permissive variants from a survey of >300 inde-
pendent patients with FSHD. In addition, we
studied >2000 control individuals and identified
additional nonpermissive chromosome variants:
4B168, 10A164, and 10B161T (fig. S3). Thus,
D4Z4 contractions on 4A161, 4A161L, 4A159,
and 4A168 chromosomes are pathogenic, and
D4Z4 contractions on 4B163, 4B168, 10A166,
10A164, 10B161T, and 10A176T chromosomes
are nonpathogenic.
We sequenced the first and last D4Z4 units
and flanking sequences in these newly identified
permissive and nonpermissive chromosomes.
(Fig. 1B and fig. S2). In support of our earlier
data, there is no common sequence in the prox-
imal D4Z4 region that unifies FSHD-permissive
chromosomes. At the distal end, all permissive
chromosomes differed very little in sequence and
all contained a canonical DUX4 poly(A) signal,
whereas nonpermissive chromosomes showed
much more sequence variation relative to the per-
missive chromosomes. The only exception, 4B163,
has a D4Z4 sequence highly identical to 4A161
but, importantly, lacks the pLAMsequence (Fig. 1).
The permissive 4A161L chromosome is identical
to 4A161 but carries an extended D4Z4 se-
quence, preceding an identical pLAM sequence
(Fig. 1B and fig. S2). Sequence analysis of the
distal D4Z4-pLAM region of the pathogenic chro-
mosome in our four families with complex repeat
array structures showed a sequence identical to
the permissive 4A161 sequence. Transfection ex-
periments with D4Z4-pLAM sequences derived
from the disease chromosomes of families F1 and
F3 showed transcript stabilities and polyadenyl-
ation efficiencies of the distal DUX4 transcript
comparable to 4A161 chromosomes (Fig. 2B).
This demonstrates that DUX4 can also be ef-
ficiently produced from these chromosomes. Al-
together, our study demonstrates that all patients
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Fig. 3. Pedigrees of FSHD1 families with complex
pathogenic chromosomes. Families F1 to F4 all
carry a hybrid D4Z4 repeat (H) that commences
with chromosome 10-type repeat units (closed
triangles) but end with 4-type repeat units (open
triangles). In family F3, a meiotic rearrangement
between chromosomes 4 and 10 generated a short
hybrid repeat structure on 4A161. In family F4,
this pathogenic repeat is located on chromosome
10 and originates from a mitotic D4Z4 contraction
in the mildly affected father that is transmitted to
his affected son. Family F5 represents a disease chro-
mosome in which, in addition to partial deletion of
the D4Z4 repeat, the region proximal to the D4Z4
repeat is also deleted (del).

































identical sequence in the last D4Z4 unit and im-
mediately flanking pLAM sequence, and it shows
that specific sequence variants unique to the per-
missive haplotypes confer pathogenicity to the
repeat irrespective of its chromosomal localiza-
tion (fig. S8).
Finally, this distal pLAM region is also pre-
served in individuals with FSHD1 in whom the
deleted region extends proximally to the D4Z4
repeat array (F5 in Fig. 3), as well as in FSHD2
patients, who have a classical FSHD phenotype
but show a similar local chromatin relaxation on
a 4A161 chromosome independent of D4Z4 re-
peat array contraction (6, 23).
Our study puts forward a plausible genetic
model for FSHD. In this model, two polymor-
phisms create a polyadenylation site for the distal
DUX4 transcript, located in the pLAM sequence.
In combination with the chromatin relaxation of
the repeat, this leads to increased DUX4 tran-
script levels. FSHD may arise through a toxic
gain of function attributable to the stabilized dis-
tal DUX4 transcript. Our study thus not only ex-
plains the striking chromosome specificity of the
disorder but also provides a genetic mechanism
that may unify the genetic observations in pa-
tients with FSHD.
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The Genetic and Molecular Basis
for Sunscreen Biosynthesis
in Cyanobacteria
Emily P. Balskus and Christopher T. Walsh*
Ultraviolet UV-A and UV-B radiation is harmful to living systems, causing damage to biological
macromolecules. An important strategy for dealing with UV exposure is the biosynthesis of small-molecule
sunscreens. Among such metabolites, the mycosporine and mycosporine-like amino acids (MAAs) are
remarkable for their wide phylogenetic distribution and their unique chemical structures. Here, we
report the identification of a MAA biosynthetic gene cluster in a cyanobacterium and the discovery of
analogous pathways in other sequenced organisms. We have expressed the cluster in a heterologous
bacterial host and characterized all four biosynthetic enzymes in vitro. In addition to clarifying the origin
of the MAAs, these efforts have revealed two unprecedented enzymatic strategies for imine formation.
Mycosporines and mycosporine-like ami-no acids (MAAs) are ultraviolet (UV)–absorbing small molecules (lmax = 310
to 360 nm) (1) that are synthesized by cyano-
bacteria, fungi, and eukaryotic micro- andmacro-
algae (2–5). These metabolites are also ingested
and accumulated by numerous marine animals.
Discovered and named for mediating light-induced
fungal sporulation (6–8), mycosporines andMAAs
are involved in many other biological processes,
includingUVphotoprotection of organisms (2–5, 9)
and their embryos (10), osmotic regulation (11),
and defense against oxidative stress (12). Addi-
tionally, their ability to prevent UV-induced skin
damage in vivo (13) has led to their commercial-
ization as Helioguard 365, a formulation containing
MAAs shinorine and porphyra-334 that is used in
skin care and cosmetic products.
Structurally this large natural-product family
is divided into two groups: the mycosporines,
which contain a single proteogenic or modified
amino acid residue linked to a cyclohexenone
core, and the MAAs, which have two such sub-
stituents (Fig. 1A). The amino acids are attached
to the central ring through imine linkages, an ar-
rangement best represented as a combination of
resonance tautomers (Fig. 1B). This extensive
conjugation facilitates absorption of UV (Fig. 1C).
Fungi produce only mycosporines, whereas cya-
nobacteria, algae, and marine organisms can syn-
thesize both mycosporines and MAAs.
The occurrence, distribution, and biology of
mycosporines and MAAs have been subjects of
intense investigation, but elucidation of the pre-
cise biochemical mechanisms underlying their
functions has been hampered by a lack of knowl-
edge regarding the molecular and genetic basis
for their biosynthesis. Previous feeding studies with
cyanobacteria and fungi revealed that the amino acid
substituents were added in the later stages of bio-
synthesis and suggested, but did not prove, that the
mycosporine core might originate from shikimate
pathway intermediate 3-dehydroquinate (14, 15).
Despite these efforts, no genes have been defin-
itively linked to mycosporine or MAA produc-
tion in any organism.
We attempted to locate candidate biosynthetic
gene clusters using a genome mining approach
prompted by the discovery of genes encoding
shikimate pathway enzymes in the genome of sea
anemone Nematostella vectensis (16), includ-
ing a dehydroquinate synthase homolog (DHQS)
adjacent to an O-methyltransferase (O-MT).
Recognizing that a methyltransferase was likely in-
volved in mycosporine assembly, we considered
the DHQS andO-MT to be candidate biosynthetic
genes.BLASTsearcheswith both protein sequences
revealed clustered homologs in genomes of dino-
flagellates, cyanobacteria, and fungi (17).
Examining the hits in their genomic contexts
revealed that open reading frames (ORFs) en-
coding DHQSs and O-MTs were accompanied
by a third conserved ORF, usually annotated as a
hypothetical protein. A conserved domain search
using this gene revealed homology to the adeno-
sine triphosphate (ATP)–grasp superfamily. As
these enzymes catalyze peptide bond formation,
we reasoned that this gene product might be in-
volved in amino acid installation. We also noted
genetic variations between cyanobacterial and
fungal clusters consistent with the structural dif-
ferences between cyanobacterial MAAs and fun-
gal mycosporines; cyanobacteria had a second
Department of Biological Chemistry and Molecular Pharmacol-
ogy, Harvard Medical School, Boston, MA 02115, USA.
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